Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Pemetrexed in Treating Patients with Metastatic Bladder Cancer

  • Li, Qing (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University) ;
  • Li, Jian-Zhang (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University) ;
  • Xu, Wan-Hai (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University) ;
  • Gao, Lin (Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University)
  • Published : 2015.05.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This pooled analysis was conducted to evaluate the efficacy and safety of pemetrexed based chemotherapy in treating patients with metastatic bladder cancer as salvage chemotherapy. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with bladder cancer were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In pemetrexed based regimens, 3 clinical studies which including 105 patients with advanced transitional cell cancer of the urothelium were considered eligible for inclusion. Pooled analysis suggested that, in all patients, pooled RR was 26.7% (28/105) for pemetrexed based regimens. Major adverse effects were neutropenia, anorexia, fatigue, and anemia in pemetrexed based treatment. Two treatment related deaths occurred with pemetrexed based treatment. Conclusion: This pooled analysis suggests that pemetrexed based regimens are associated with mild activity and good tolerability in treating patients with metastatic bladder cancer.

Keywords

References

  1. Babjuk M. et al (2011). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol, 59, 997-1008. https://doi.org/10.1016/j.eururo.2011.03.017
  2. Bamias A, Aravantinos G, Deliveliotis C, et al (2004). Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol, 22, 220-8.
  3. Dreicer R, Li H, Cooney MM, et al (2008). Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer, 112, 2671-5. https://doi.org/10.1002/cncr.23503
  4. Galsky MD, Mironov S, Iasonos A, et al (2007). Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs, 25, 265-70. https://doi.org/10.1007/s10637-006-9020-9
  5. Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
  6. Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90. https://doi.org/10.7314/APJCP.2014.15.16.6587
  7. Lu YY, Huang XE, Cao J (2013). Phase II study on Javanica oil emulsion injection (Yadanzi$^{(R)}$) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791
  8. McCaffrey JA, Hilton S, Mazumdar M, et al (1997). Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol, 15, 1853-57.
  9. Margulis V. et al (2009). Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 115, 1224-33. https://doi.org/10.1002/cncr.24135
  10. Munoz JJ, Ellison LM (2000). Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol, 164, 1523-5. https://doi.org/10.1016/S0022-5347(05)67019-X
  11. Ploeg M, Aben KK, Kiemeney LA (2009). The present and future burden of urinary bladder cancer in the world. World J Urol, 27, 289-93. https://doi.org/10.1007/s00345-009-0383-3
  12. Roth BJ, Dreicer R, Einhorn LH, et al (1994). Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 12, 2264-70.
  13. Sweeney C, Roth B, Kabbinavar F, et al (2006). Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol, 24, 3451-7. https://doi.org/10.1200/JCO.2005.03.6699
  14. Tian GY, Miu M, Huang XE (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8. https://doi.org/10.7314/APJCP.2014.15.19.8475
  15. von der Maase H, Hansen S, et al (2000). Gemcitabine and cisplatin versus methotrextate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18, 3068-77.
  16. Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
  17. Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. https://doi.org/10.7314/APJCP.2014.15.14.5941

Cited by

  1. Evolving Treatment of Advanced Urothelial Cancer vol.13, pp.5, 2017, https://doi.org/10.1200/JOP.2017.022137